REGN vs VCEL · P/E 14, rev $14.34B vs P/E 835, rev $237.2M
Regeneron Pharmaceuticals Inc (REGN) versus Vericel Corp Ord (VCEL) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Vericel Corp Ord (VCEL) is a biotechnology company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported VCEL revenue for 2024-12-31 was $237.2M. Net income was $10.4M. Revenue was up 20.1% from 2023-12-31 to 2024-12-31. VCEL currently screens at market cap $2.10B and trailing P/E 834.8.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. VCEL currently screens at market cap $2.10B and trailing P/E 834.8.
Not investment advice. Open the REGN and VCEL stock pages for the full models.
Not investment advice.